Reata’s mission is to develop novel therapeutics for patients with serious and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Our lead product candidates, bardoxolone methyl and omaveloxolone, are Nrf2 activators. Bardoxolone methyl is currently in a pivotal Phase 2/3 (CARDINAL) study for the treatment of chronic kidney disease caused by Alport syndrome and a pivotal Phase 3 (FALCON) study for treatment of ADPKD.